SEC Form 4 · accession 0001567619-18-008731
CytomX Therapeutics, Inc. · CTMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James R Meyers
Director
Period of report
Dec 20, 2018
Accepted (ET)
Dec 27, 2018 · 12:42 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501989
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $14.04 | Dec 20, 2018 | A | 28,000 | A | — | Dec 19, 2028 | Common Stock | 28,000 | 28,000 | D |
Explanation of responses
- F11/36th of the shares subject to the option vest on each monthly anniversary measured from December 20, 2018 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.